Objective To explore the correlation between quantitative parameters of contrast⁃enhanced ultrasound and clinicopathological parameters and lesion neovascularization in patients with ovarian cancer. Methods Employing retrospective study method, 105 patients with ovarian cancer (the ovarian cancer group) and 56 patients with benign ovarian tumors (the control group) were selected as the research subjects. The quantitative parameters of contrast⁃enhanced ultrasound with respect to arrival time (AT), time to peak (TTP), peak intensity (PI), and enhancement intensity (EI) were compared between patients of the two groups. Subgroup analysis was conducted on the ovarian cancer group to compare the differences in quantitative parameters of contrast⁃enhanced ultrasound between patients in various subgroups, and to analyze the correlation between quantitative parameters of contrast⁃enhanced ultrasound and lesion microvascular density (MVD) in the ovarian cancer group. Results The ovarian cancer group exhibited shorter AT and TTP, whereas higher EI and PI as compared with the control group (P<0.05). Ovarian cancer patients with low⁃moderate differentiation, International Federation of Gynecology and Obstetrics (FIGO) in stage Ⅲ, lymphatic metastasis, and high MVD obtained lower AT and TTP, while higher EI and PI as compared with ovarian cancer patients with high differentiation, FIGO in stage Ⅰ-Ⅱ, without lymphatic metastasis, and with low MVD (P<0.05). AT and TTP negatively correlated with MVD, while EI and PI positively correlated with MVD in the ovarian cancer group (P<0.05). Conclusion Among patients with ovarian cancer, quantitative parameters of contrast⁃enhanced ultrasound AT and TTP are shorter, while EI and PI increase. Ovarian cancer patients with low⁃moderate differentiation, FIGO in stage Ⅲ, lymphatic metastasis, and high MVD obtain shorter AT and TTP, and higher EI and PI. The shorter the AT and TTP are, or the higher the EI and PI are, the stronger the lesion neovascularization activity in patients with ovarian cancer is.